Effectiveness of bivalent mRNA COVID-19 vaccines in preventing SARS-CoV-2 infection in children and adolescents ages 5 to 17
About The Study: The bivalent COVID-19 vaccines protected children and adolescents against SARS-CoV-2 infection and symptomatic COVID-19 in this study including 2,959 participants ages 5 to 17 years. These data demonstrate the benefit of COVID-19 vaccine in children and adolescents. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations.
Authors: Leora R. Feldstein, Ph.D., of the Centers for Disease Control and Prevention in Atlanta, is the corresponding author.
To access the embargoed study: Visit our For The Media website ...














